Stem Cell Derived Cardiomyocytes in Drug Safety Evaluations: Lessons Learned from the Comprehensive in Vitro Proarrhythmia Assay (CiPA) Initiative.

Tuesday, 5 April 2016 at 11:15

Add to Calendar ▼2016-04-05 11:15:002016-04-05 12:15:00Europe/LondonStem Cell Derived Cardiomyocytes in Drug Safety Evaluations: Lessons Learned from the Comprehensive in Vitro Proarrhythmia Assay (CiPA) Initiative.Stem Cells in Drug Discovery 2016 in Cambridge, UKCambridge, UKSELECTBIOenquiries@selectbiosciences.com

This presentation will describe the critical role of human stem cell derived cardiomyocytes in the CiPA initiative, lessons learned as the project moves towards completion, along with their future role in preclinical cardiac safety testing.

Gary Gintant, Senior Research Fellow, Abbvie

Gary Gintant

Dr. Gary Gintant is Senior Research Fellow in the Dept. of Integrative Pharmacology, Integrated Science and Technology, at AbbVie. He is involved in multiple internal drug discovery and safety initiatives internally; external activities include various cardiac safety initiatives (such as ILSI/HESI Proarrhythmia Models Project, the Cardiac Safety Research Consortium, and the Comprehensive in Vitro Proarrhythmia Assay Initiative) while serving on various journal editorial boards, NIH study sections, and Safety Pharmacology Society committees. Research interests include cardiovascular pharmacology, cellular electrophysiology/ion channels, arrhythmias, application of stem-cell derived cells and tissues to drug discovery efforts, and translational medicine. He gained his MA, M.Phil. and PhD degrees from the College of Physicians and Surgeons of Columbia University.